新一代药物GLP-1类似物对2型糖尿病患者β细胞功能的保护  

Preservation of β-cell function in type 2 diabetes by GLP-1 based therapy

作　　者：杨文英[1] 

机构地区：[1]中日友好医院内分泌科,北京100029

出　　处：《中华内分泌代谢杂志》2008年第6期I0001-I0005,共5页Chinese Journal of Endocrinology and Metabolism

摘　　要：2型糖尿病以β细胞功能进行性减退和β细胞量的减少为特点。高血糖、炎性因子和游离脂肪酸等与肥胖、胰岛素抵抗及β细胞凋亡密切相关。保护β细胞、针对β细胞功能减退的治疗是2型糖尿病治疗的关键。胰高血糖素样肽1（GLP-1）是肠道促胰岛激素，它的多重生物学效应可以改善2型糖尿病的病理生理学状况。GLP-1对血糖的良好控制以及对β细胞功能的改善作用使其备受瞩目。本文围绕2型糖尿病发病的重要环节——β细胞功能，阐述了β细胞功能减退和β细胞量减少的机制，并综述了GLP-1保护β细胞功能和增加β细胞量的研究进展。Type 2 diabetes is characterized by deteriorated β-cell function and progressive loss of β-cell mass. Pancreatic islets are a target of high concentrations of glucose, pro-inflammatory cytokines and free fatty acid levels, which are associated with obesity, insulin resistance and β-cell apoptosis. Therapy targeting β-cell dysfunction is crucial in the treatment of type 2 diabetes. GLP-1, one of the incretin hormones, has been demonstrated to improve glycaemic control and β-cell function through its multiple physiological effects. In this review, the mechanisms involved in β-cell dysfunction and β-cell loss are addressed, and the updates in GLP-1 based therapy for the preservation of β-cell mass and β-cell function in type 2 diabetes are also reviewed.

关 键 词：糖尿病 2型 胰岛Β细胞 胰升糖素样肽1 

分 类 号：R587.1[医药卫生—内分泌] R395[医药卫生—内科学]